Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak
OncologyEducation presents MedOncNow
Release Date: 10/07/2025
Choosing in Advanced NSCLC - Without AGA, and EGFR+ with Dr. Natasha Leighl
OncologyEducation presents MedOncNow
In this episode, Dr. Natasha Leighl takes us through practical aspects of choosing treatments in advanced NSCLC without AGA and then in EGFR + NSCLC. We discuss treatments that are routinely available in clinic.
info_outline
Sequencing in Advanced Colorectal Cancer - with Dr. Scott Berry
OncologyEducation presents MedOncNow
In this episode, Dr. Scott Berry takes us through practical discussions on sequencing the increasing available treatment options for Advanced Colorectal cancer.
info_outline
BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin
OncologyEducation presents MedOncNow
As we now access Encorafenib + Cetuximab + Folfox via a Pfizer sponsored PSP for the he first line treatment Braf V600e mutated, RAS wt, dMMR/MSS metastatic Colorectal cancer, Dr. Rachel Goodwin takes us through the regimen, its practical use and efficacy and toxicity management.
info_outline
Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak
OncologyEducation presents MedOncNow
As we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management.
info_outline
TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley
OncologyEducation presents MedOncNow
As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management
info_outline
Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala
OncologyEducation presents MedOncNow
In this episode of MedOncNow, Dr. Hatim Karachiwala discusses where IPI/NIVO is positioned in the first-line treatment options of advanced HCC. We discuss the regimen's efficacy with a focus on toxicity management. This is particularly timely as BMS has a compassionate access program for Ipilimumab and Nivolumab for advanced HCC.
info_outline
IPI/NIVO for mCRC with Dr. Sharlene Gill
OncologyEducation presents MedOncNow
In this episode of MedOncNow, Dr. Sharlene Gill takes us through the evolving changes in the treatment of dMMR/MSI-H mCRC. Given that BMS has a company-sponsored PSP program, I felt it timely to discuss how Ipilimumab and Nivolumab fits into our treatment strategy.
info_outline
The CHALLENGE to Move and Survive: Exercise After Adjuvant Colon Cancer Treatment with Dr. Christopher Booth
OncologyEducation presents MedOncNow
In this episode of MedOncNow, Dr. Christopher Booth discusses how 3 years of a structured exercise program after adjuvant chemotherapy for resected colon cancer can improve survival. This is an affordable, accessible and evidence-based strategy that can be incorporated into practice tomorrow.
info_outline
Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa
OncologyEducation presents MedOncNow
In this episode of MedOncNow, Dr. Kevin Jao discusses Amivantamab + Lazertinib in the first-line treatment of EGFR-mutated NSCLC and how it fits into the treatment landscape. This is timely, as Johnson & Johnson has a time-limited access program to Ami-Laz for EGFR-mutated NSCLC, as per the Mariposa Regimen. More information in episodes 2 and 3. Proudly partnering with Oncology Education for the 2025 season. MedOncNow has been made possible by the generous unrestricted support of BMS, Eisai, Johnson and Jonhson, Merck, Pfizer and Roche Canada.
info_outline
Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2
OncologyEducation presents MedOncNow
In this episode of MedOncNow, Dr. Christine Brezden-Masley explores the clinical impact of Zolbetuximab in gastric and GEJ cancers, covering patient selection, treatment integration, and implications for systemic therapy delivery. This is timely as ASTELLAS is funding both testing for Claudin 18.2 and access to Zolbetuximab for Gastric and GEJ cancers across Canada. 🎧 Catch up on Part 1 for insights into Claudin 18.2 testing and its role in guiding therapy decisions.
info_outlineAs we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management.